# A Prospective, Multi-center Registry to Evaluate Safety and Efficacy of Hativ® ELectrocardiogram Monitoring on Patients with Hemodialysis

Study · id `cardio:ct-nct06688565` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06688565](<https://clinicaltrials.gov/study/NCT06688565>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06688565

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT06688565. Allocation not applicable; no masking; primary purpose diagnostic. Start 2024-05-13 (actual); primary completion 2025-05-13 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Not applicable
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT06688565, source copy `cardio:ctgov-nct06688565-2024-11-14`, retrieved 2026-10-26)
- Started: 2024-05-13 (actual) (ClinicalTrials.gov record NCT06688565, source copy `cardio:ctgov-nct06688565-2024-11-14`, retrieved 2026-10-26)
- Primary completion: 2025-05-13 (anticipated) (ClinicalTrials.gov record NCT06688565, source copy `cardio:ctgov-nct06688565-2024-11-14`, retrieved 2026-10-26)
- Completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT06688565, source copy `cardio:ctgov-nct06688565-2024-11-14`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06688565, source copy `cardio:ctgov-nct06688565-2024-11-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06688565-2024-11-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Prospective, Multi-center Registry to Evaluate Safety and Efficacy of Hativ® ELectrocardiogram Monitoring on Patients with Hemodialysis
- Condition: End-Stage Kidney Disease
- Condition: Hemodialysis
- Intervention (Device): Hativ® electrocardiogram monitoring
- Lead sponsor: Hallym University Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Hallym University Medical Center (`cardio:org-hallym-university-medical-center`)

## Provenance

Content hash: 5047f8a00eb20b0792d0c8564e5d7bac8f02b46ebb667b64ac5e8fcf89049619
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
